On May 14, 2008, ViroPharma Incorporated (the “Company”), through a wholly owned subsidiary, ViroPharma Limited, entered into leases of two floors of a commercial building in Maidenhead, Berkshire, United Kingdom, comprising approximately 8,000 square feet of office space, which will serve as the Company’s headquarters in the United Kingdom. The leases expire ten years from the date of the leases. The leases call for a security deposit of £211,712 and annual lease payments of £120,120 during the first twelve months of the leases and annual lease payments of £240,240 during the remainder of the term of the leases. ViroPharma Limited has the right to break each of the leases at the fifth anniversary of the term upon the provision of appropriate notices and payment of an aggregate break fee of £35,285. The leases also included a parent company guarantee by ViroPharma Incorporated of the lease obligations incurred by ViroPharma Limited.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.